News
Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of ...
Popular Western medicines for diseases including cancer and diabetes have been caught in the escalating U.S.-China trade war, ...
First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy ...
The FDA granted approval for the use of Skytrofa (lonapegsomatropin) in September 2021 for the treatment of pediatric ...
David Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard ...
Patients with solid tumor malignancies had better survival after ICI therapy if they were obese than if they had a normal BMI.
AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European ...
Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization ...
10d
MyChesCo on MSNFDA Approves AstraZeneca’s IMFINZI® for Muscle-Invasive Bladder CancerAstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer ...
EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...
The European Commission has approved a new regimen from AstraZeneca, which combines the company’s durvalumab with ...
Matt Galsky, MD, discusses the phase 3 NIAGARA trial that led to the recent FDA approval of durvalumab in muscle-invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results